新辅助静脉化疗治疗中晚期宫颈癌患者的临床效果及机制分析

Clinical Effect of Neoadjuvant Chemotherapy on Patients with Advanced Cervical Cancer and Its Mechanisms

目的:探讨新辅助静脉化疗对中晚期宫颈癌患者的临床疗效及其可能作用机制。方法:收集于我院就诊或住院治疗的60例宫颈癌患者,根据治疗方案不同分为实验组和对照组,每组各30例。对照组患者采用放疗方案,实验组患者在对照组基础上应用新辅助静脉化疗方案,21 d为一疗程,共2个疗程。治疗期间密切注意患者的生命体征,并对出现的并发症进行及时治疗。治疗结束后,对患者的血清肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF)、患者副作用发生率以及临床疗效进行检测并比较。结果:与治疗前相比,两组患者治疗后的血清TNF-α、VEGF水平均显著下降(P<0.05);与对照组相比,实验组患者治疗后的血清TNF-α、VEGF水平及副作用发生率较低(P<0.05),临床治疗总有效率较高(P<0.05)。结论:新辅助静脉化疗能够显著提高中晚期宫颈癌患者的临床疗效并减少化疗相关的不良反应,这可能与其降低中晚期宫颈癌患者血清TNF-α、VEGF水平有关。

Objective： To investigate the effect of neoadjuvant chemotherapy on patients with advanced cervical cancer and its possible mechanism. Methods： 60 cases of cervical cancer from our hospital were collected and divided into the experimental group and the control group with 30 cases in each group. Patients in the control group were treated with radiotherapy, based on the treatment of the control group, the new adjuvant intrayenous chemotherapy were used on the patients in the experimental group for 2 courses, as 21d for one course. Pay close attention to the Patients＇ vital signs during the treatment, and apply timely treatment to complications. After the treatment, the serum levels of tumor necrosis factor-α （TNF-α）, vascular endothelial growth factor （VEGF）, the incidence of side effects and clinical efficacy were detected and compared. Results： Compared with before treatment, the serum TNF-α, VEGF levels were signifi- cantly decreased of the two groups of patients after treatment, （P〈0.05）; compared with the control group, serum TNF-α, VEGF levels and incidence of side effects of the experimental group arc lower aRer treatment （P〈0.05）, the clinical total efficiency was higher （P〈0. 05）. Conclusion： Neoadjuvant chemotherapy could enhance the clinical efficacy and reduce the side effects in the trcatrnent of advanced cervical cancer, which might be related to the decrease of serum levels of TNF-α, VEGF.